Hormone Responsibility
Promoting Animal Reproductive Health

R&D Department

Research and Development Department(R&D)

Administration Department

Administration Management Department

Sales Department

Sale Department

Technical Service Department

Technical Service Department

 Ningbo Second Hormone Factory was established in 1988, and it is a high-tech enterprise specializing in veterinary reproductive hormones, integrating raw material supply, R&D, production, sales, and service. It was the first enterprise in the veterinary hormone industry to pass the new GMP certification and has been honored with titles such as "National High-Tech Enterprise," "Zhejiang Provincial 'Hidden Champion' Cultivation Enterprise," "Cixi City's 'Top 100' Enterprise," and "Cixi City's 'Top 100 Taxpayer' Enterprise."

Our company provides a comprehensive portfolio of veterinary reproductive hormones, which are widely used in swine, cattle, sheep, fish, pets, and other species. Adhering to the mission of "Delivering Superior Quality in the Industry and Building a World-Class Brand," we primarily research and produce our own key raw materials. Leveraging nearly four decades of experience in human pharmaceuticals, we adopt advanced drug manufacturing technologies to enhance the overall quality of veterinary hormone preparations.

The company adheres to a dual approach of independent R&D and industry-academia-research collaboration, partnering with leading domestic universities and research institutions to develop cutting-edge veterinary hormone products and application technologies. To date, the company’s R&D passed 20 national new veterinary drug registrations (including 12 Category II new veterinary drugs), with 2–3 new veterinary drugs submitted for approval annually. It has led or participated in the formulation of 21 national standards and obtained 32 national authorized patents for its independent innovations, achieving comprehensive coverage of all core products.

In 2023, Busherelin (Buserelin Acetate for Injection) and Beierqi (Carbetocin Injection) were approved as national Category II new veterinary drugs for both APIs and formulations. Tongyunbao (Altrenogest Tablets) was approved as a Category IV new veterinary drug, representing a dosage form upgrade and an international innovation.

In 2024, the oxytocin active pharmaceutical ingredient (API) declared by the enterprise was approved as a National Category III New Veterinary Drug, filling the gap in quality standards for veterinary oxytocin APIs in China.

In 2025, company’s progesterone vaginal instert (for sheep/goat use) was approved as a Category V new veterinary drug, marking another domestic innovation and filling a gap in the Chinese market.

The company has always adhered to its mission of "Hormone Expertise, Promoting Animal Reproductive Health," striving to develop high-quality veterinary hormone products for its customers. It has established multiple protocols tailored to different farming scales and application scenarios, including batch production technology for sows, estrus synchronization programs for dairy cows, as well as superovulation, synchronization, and induced estrus protocols for sheep. By providing comprehensive and efficient breeding solutions, the company actively contributes to the advancement of efficient reproduction and innovation in domestic animal husbandry, thereby helping to ensure food safety for humans.